Proton Therapy for Chordoma and Chondrosarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation for treatment of chordomas and chondrosarcomas.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is proton therapy safe for treating chordoma and chondrosarcoma?
Proton therapy, including its various forms like intensity-modulated proton therapy (IMPT), has been used in clinical trials for treating chordoma and chondrosarcoma, showing it can be administered safely. Studies have reported on its use in different parts of the body, such as the spine and skull base, with a focus on managing side effects and ensuring precise delivery of treatment.12345
How is proton therapy different from other treatments for chordoma and chondrosarcoma?
Proton therapy is unique because it can deliver high doses of radiation more precisely to tumors like chordoma and chondrosarcoma, which are often located near critical structures, reducing damage to surrounding healthy tissue. This makes it particularly effective for tumors that are considered radioresistant and require high radiation doses.14567
What data supports the effectiveness of the treatment Proton Therapy for Chordoma and Chondrosarcoma?
Research shows that proton therapy, including advanced forms like intensity-modulated proton therapy (IMPT), is effective for treating chordoma and chondrosarcoma, especially in challenging areas like the skull base and spine. Studies indicate that it can safely deliver higher doses of radiation to tumors while minimizing damage to surrounding healthy tissues.14589
Are You a Good Fit for This Trial?
This trial is for adults (18+) with confirmed chordoma or chondrosarcoma in the skull and spine, without metastatic disease. Participants must be fairly active (ECOG ≤2), have good bone marrow function, and not be pregnant. They can't join if they've had other cancers in the last two years or are on another treatment study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Feasibility
Evaluate the feasibility and acute side effects of proton therapy for the first 12 participants
Phase II Treatment
Participants receive proton radiation therapy with a total dose of 72.00 to 79.2 Gy(RBE) in 40-44 fractions
Follow-up
Participants are monitored for acute and late toxicity, as well as clinical outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Proton Therapy
Proton Therapy is already approved in United States, European Union, Canada, Japan for the following indications:
- Head and neck cancer
- Pediatric cancers
- Spine tumors
- Breast cancer
- Sarcoma
- Brain tumors
- Prostate cancer
- Head and neck cancer
- Pediatric cancers
- Spine tumors
- Breast cancer
- Sarcoma
- Brain tumors
- Prostate cancer
- Head and neck cancer
- Pediatric cancers
- Spine tumors
- Breast cancer
- Sarcoma
- Brain tumors
- Prostate cancer
- Head and neck cancer
- Pediatric cancers
- Spine tumors
- Breast cancer
- Sarcoma
- Brain tumors
- Prostate cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor